Penny stocks, where information will often play a pivotal role in shaping trading outcomes. Press releases can act as potent catalysts, swiftly influencing the trajectory of these affordable equities.
Today, this article sets out on an exploration of four penny stocks that have recently unveiled noteworthy news, presenting potential opportunities for investors. By focusing on these significant developments, the aim is to analyze how these announcements have the potential to expedite the growth and momentum of these stocks.
Epazz Inc. (OTC: EPAZ):
EPAZ and its subsidiary, ZenaDrone, are making waves in the drone technology market, and their recent announcement on July 12, 2023, highlights a significant development. ZenaDrone has successfully secured asset-based funding for the initial manufacturing and deployment of 20 ZenaDrone 1000s in Ireland, paving the way for Drone as a Service (DaaS) operations. This milestone not only demonstrates the company's commitment to innovation but also reflects the growing demand for advanced drone solutions.
Each deployed ZenaDrone 1000 is projected to generate over $100,000 per year, showcasing the tremendous potential for revenue generation in the drone services market. The estimated market size is expected to reach $189.4 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 38.9% during the forecast period, according to Fortune Business Insights.
The deployment of these 20 drones in Ireland will serve various sectors, including Irish farmers, businesses, and government agencies. Irish farmers, in particular, will benefit from advanced-precision agriculture drones that can monitor plant health and efficiently spray weeds. Additionally, the drones will play a crucial role in emergency response as an integrated part of the first-responder system, aiding the police force and fire departments.
Epazz Inc.'s CEO and Director, Shaun Passley, Ph.D., expressed enthusiasm about this milestone and emphasized the positive impact the ZenaDrone 1000 will have on the agriculture industry. The drone's advanced features, such as a high-quality camera, autonomous flight capabilities, and a multi-sensor system, enable users to capture stunning aerial photographs and videos while ensuring safe operations even in challenging weather conditions.
This recent development aligns with Epazz Inc.'s overall vision of delivering cutting-edge solutions and establishing a strong global presence. ZenaDrone's expansion into Ireland signifies the company's commitment to working with Irish farmers to upgrade their farms with the latest technologies. Furthermore, ZenaDrone has been actively pursuing customers throughout Europe, with the expectation that ongoing deployments will contribute to a steady revenue stream in the region. Additionally, plans to expand DaaS operations into Germany further solidify their growth strategy.
Epazz Inc. and ZenaDrone have positioned themselves as disruptors in the drone technology market, gaining recognition in various sectors, including the military, agriculture, and commercial industries. Their dedication to innovation is evident through the pursuit of AI patents and the establishment of a strong intellectual property rights framework.
With funding secured for the ZenaDrone 1000s and their expansion into Ireland, Epazz Inc. and ZenaDrone are poised to capitalize on the growing demand for advanced drone solutions. Their relentless pursuit of excellence in drone technology positions them as an enticing emerging player the industry
BioPower Operations Corporation (OTC: BOPO), also known as HYFI Corp., is a company operating in the green energy, environmental, and infrastructure markets. They recently made a significant announcement regarding their joint venture with POWGEX ENERGY in South Africa, securing a major order to build up to 30 gigawatts (GW) of green electricity. The initial phase involves constructing a 1 GW solar power plant in the populous Municipalities of Mpumalanga, South Africa, with the potential for future expansion.
BioPower/HYFI's ability to secure this order highlights their expertise in renewable energy initiatives and their growing presence in the South African market. The project installations for the first 1 GW are scheduled to begin in Q1 2024, with an estimated project cost of $2.5 billion. They have selected a market-leading solar photovoltaic and battery storage Original Equipment Manufacturer to provide and install the initial 1 GW of deliverables. Discussions are also underway with a world-leading Engineering, Procurement, and Construction (EPC) and Operations and Maintenance provider for the project.
In May, BioPower/HYFI announced they had expanded their consortium of interested financial institutions, with Signet Capital serving as the lead financial advisor. Signet Capital will arrange a $450 million private placement for the initial phase of the project, facilitating BioPower/HYFI's structured finance needs. Additionally, POWGEX Energy will invest $50 million in BioPower Common Stock, acquiring a 15% stake in BioPower and further strengthening the strategic partnership between the companies.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical-stage pharmaceutical company specializing in the development of innovative therapies for hard-to-treat tumors and viruses. With a growing pipeline and a focus on addressing unmet medical needs, Moleculin is at the forefront of advancing treatment options for challenging medical conditions.
On July 13, 2023, Moleculin Biotech made a significant announcement that highlights their ongoing commitment to developing breakthrough treatments. The company released positive data from the successful Phase 1 trial of their lead program, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia (AML). This announcement marks a major milestone in their efforts to address the urgent medical needs of AML patients.
The data from the completed MB-105 European Phase 1 clinical trial, published in the esteemed British Journal of Cancer Research, demonstrates the remarkable efficacy and safety of Annamycin as a single-agent treatment for AML. Importantly, the findings revealed no evidence of cardiotoxicity in any of the study participants, even in those who received cumulative doses exceeding traditional anthracycline limits.
By successfully advancing Annamycin through the clinical trial process, Moleculin is taking significant steps towards providing a potentially life-changing treatment option for individuals affected by relapsed or refractory AML
Synaptogenix, Inc. (NASDAQ: SNPX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases. With a focus on regenerative therapeutics, Synaptogenix has conducted extensive clinical and preclinical studies on its lead candidate, Bryostatin-1, primarily for the treatment of Alzheimer's disease. The company's research has also demonstrated the potential of Bryostatin-1 in addressing Fragile X syndrome, multiple sclerosis, stroke, traumatic brain injury, and other neurodegenerative disorders. Notably, the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 in the treatment of Fragile X syndrome. Leveraging the safety data from over 1,500 individuals in cancer studies, Bryostatin-1 has established a strong foundation for its clinical trial designs.
On July 13, 2023, SNPX announced a significant development. An abstract highlighting secondary endpoint data from its NIH-sponsored Phase 2 Bryostatin-1 trial has been accepted for presentation at the 11th International Brain Research Organization (IBRO) World Congress of Neuroscience, which will be held in September 2023 in Spain.
The Phase 2 trial of Bryostatin-1 examined two patient cohorts: the Moderate Cohort and the Severe Cohort. While the Moderate Cohort did not show significant benefits, the Severe Cohort, representing patients with advanced Alzheimer's disease, demonstrated statistically significant achievement of pre-specified secondary endpoints. Furthermore, exploratory analysis indicated positive results for this Severe Cohort, supporting Bryostatin-1's potential to prevent cognitive decline in severe Alzheimer's disease patients.
Dr. Alan Tuchman, the CEO of Synaptogenix, expressed confidence in the Phase 2 trial results and the abstract's acceptance by IBRO. The company remains committed to advancing the development of Bryostatin-1, exploring strategic partnerships for non-dilutive investments, and creating value for shareholders through the discovery of novel therapeutics targeting life-altering neurodegenerative diseases.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit CapitalGainsReport.com/Disclaimer for full disclaimer.
Mark McKelvie
Editor
CapitalGainsReport
585 301 7700
MarkrMcKelvie@gmail.com
.
EPAZZ, INC. 
